Molecular Medicine

, Volume 21, Issue 1, pp 410–419 | Cite as

A Selective Novel Peroxisome Proliferator-Activated Receptor (PPAR)-α Antagonist Induces Apoptosis and Inhibits Proliferation of CLL Cells In Vitro and In Vivo

  • Davorka Messmer
  • Kymmy Lorrain
  • Karin Stebbins
  • Yalda Bravo
  • Nicholas Stock
  • Geraldine Cabrera
  • Lucia Correa
  • Austin Chen
  • Jason Jacintho
  • Nicholas Chiorazzi
  • Xiao Jie Yan
  • David Spaner
  • Peppi Prasit
  • Daniel Lorrain
Research Article


Tumor-specific metabolic changes can reveal new therapeutic targets. Our findings implicate a supporting role for fatty acid metabolism in chronic lymphocytic leukemia (CLL) cell survival. Peroxisome proliferator-activated receptor (PPAR)-α, a major transcriptional regulator of fatty acid oxidation, was recently shown to be upregulated in CLL. To evaluate PPARα as a potential therapeutic target, we developed a highly selective, potent small molecule antagonist of PPARα, NXT629. NXT629 inhibited agonist-induced transcription of PPARα-regulated genes, demonstrating target engagement in CLL cells. Furthermore, NXT629 induced apoptosis of CLL cells even in the presence of a protective microenvironment. To mimic the proliferative lymphoid compartment of CLL, we examined the activity of NXT629 on CLL cells that were stimulated to proliferate in vitro. NXT629 reduced the number of leukemia cells undergoing cell division. In addition, in two xenograft mouse models of CLL (one a model for nondividing and one for dividing CLL), NXT629 reduced the number of viable CLL cells in vivo. Overall, these results suggest that fatty acid metabolism promotes survival and proliferation of primary CLL cells and that inhibiting PPARα gene regulation could be a new therapeutic approach to treating CLL.



We would like to thank all employees of Inception Sciences for their support and contribution of this program.

Supplementary material

10020_2015_2101410_MOESM1_ESM.pdf (1.3 mb)
Supplementary material, approximately 1300 KB.


  1. 1.
    Landis SH, Murray T, Bolden S, Wingo PA. (1999) Cancer statistics, 1999. CA Cancer J. Clin. 49:8–31.CrossRefGoogle Scholar
  2. 2.
    Tsimberidou AM, Keating MJ. (2009) Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer. 115:2824–36.CrossRefGoogle Scholar
  3. 3.
    Pleyer L, Egle A, Hartmann TN, Greil R. (2009) Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nat. Rev. Clin. Oncol. 6:405–18.CrossRefGoogle Scholar
  4. 4.
    Friedberg JW, et al. (2010) Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 115:2578–85.CrossRefGoogle Scholar
  5. 5.
    Buchner M, et al. (2010) Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 115:4497–506.CrossRefGoogle Scholar
  6. 6.
    Quiroga MP, et al. (2009) B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 114:1029–37.CrossRefGoogle Scholar
  7. 7.
    Foa R, Guarini A. (2013) A mechanism-driven treatment for chronic lymphocytic leukemia? N. Engl. J. Med. 369:85–7.CrossRefGoogle Scholar
  8. 8.
    Herman SE, et al. (2010) Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 116:2078–88.CrossRefGoogle Scholar
  9. 9.
    Hoellenriegel J, et al. (2011) The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 118:3603–12.CrossRefGoogle Scholar
  10. 10.
    Warburg O. (1956) On respiratory impairment in cancer cells. Science. 124:269–70.PubMedGoogle Scholar
  11. 11.
    Warburg O. (1956) On the origin of cancer cells. Science. 123:309–14.CrossRefGoogle Scholar
  12. 12.
    Carracedo A, et al. (2012) A metabolic prosurvival role for PML in breast cancer. J. Clin. Invest. 122:3088–100.CrossRefGoogle Scholar
  13. 13.
    Chang NW, Wu CT, Chen DR, Yeh CY, Lin C. (2013) High levels of arachidonic acid and peroxisome proliferator-activated receptor-alpha in breast cancer tissues are associated with promoting cancer cell proliferation. J. Nutr. Biochem. 24:274–81.CrossRefGoogle Scholar
  14. 14.
    Nieman KM, et al. (2011) Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat. Med. 17:1498–503.CrossRefGoogle Scholar
  15. 15.
    Abu Aboud O, Wettersten HI, Weiss RH. (2013) Inhibition of PPARalpha induces cell cycle arrest and apoptosis, and synergizes with glycolysis inhibition in kidney cancer cells. PLoS One. 8:e71115.CrossRefGoogle Scholar
  16. 16.
    Collett GP, et al. (2000) Peroxisome proliferator-activated receptor alpha is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma. Clin. Cancer Res. 6:3241–8.PubMedGoogle Scholar
  17. 17.
    Kamphorst JJ, et al. (2013) Hypoxic and Rastransformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc. Natl. Acad. Sci. U. S. A. 110:8882–7.CrossRefGoogle Scholar
  18. 18.
    Napal L, Marrero PF, Haro D. (2005) An intronic peroxisome proliferator-activated receptor-binding sequence mediates fatty acid induction of the human carnitine palmitoyltransferase 1A. J. Mol. Biol. 354:751–9.CrossRefGoogle Scholar
  19. 19.
    Samudio I, et al. (2010) Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J. Clin. Invest. 120:142–56.CrossRefGoogle Scholar
  20. 20.
    Ito K, et al. (2012) A PML-PPAR-delta pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat. Med. 18:1350–8.CrossRefGoogle Scholar
  21. 21.
    Fu J, et al. (2003) Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature. 425:90–3.CrossRefGoogle Scholar
  22. 22.
    Pirat C, et al. (2012) Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators. J. Med. Chem. 55:4027–61.CrossRefGoogle Scholar
  23. 23.
    Spaner DE, et al. (2013) PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia. Leukemia. 27:1090–9.CrossRefGoogle Scholar
  24. 24.
    Bravo Y, et al. (2014) Identification of the first potent, selective and bioavailable PPARa antagonist. Bioorg. Med. Chem. Lett. 24:2267–72.CrossRefGoogle Scholar
  25. 25.
    Kipps TJ. (2001) Chronic Lymphocytic Leukemia and Related Diseases. In: Williams Hematology. 6th ed. Beutler E, Lichtman MA, Coller BA, Kipps TJ, Seligsohn U (eds.). McGraw Hill Publishers, New York, pp. 1163–1194.Google Scholar
  26. 26.
    Gao J, et al. (2010) Characterization of OP9 as authentic mesenchymal stem cell line. J. Genet. Genomics. 37:475–82.CrossRefGoogle Scholar
  27. 27.
    Rakhshandehroo M, et al. (2007) Comprehensive analysis of PPARalpha-dependent regulation of hepatic lipid metabolism by expression profiling. PPAR Res. 2007:26839.CrossRefGoogle Scholar
  28. 28.
    Bouwens M, Afman LA, Muller M. (2007) Fasting induces changes in peripheral blood mononuclear cell gene expression profiles related to increases in fatty acid beta-oxidation: functional role of peroxisome proliferator activated receptor alpha in human peripheral blood mononuclear cells. Am. J. Clin. Nutr. 86:1515–23.CrossRefGoogle Scholar
  29. 29.
    Sierra ML, et al. (2007) Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents. J. Med. Chem. 50:685–95.CrossRefGoogle Scholar
  30. 30.
    Tung S, et al. (2013) PPARalpha and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia. Blood. 122:969–80.CrossRefGoogle Scholar
  31. 31.
    Burger M, et al. (2005) Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 106:1824–30.CrossRefGoogle Scholar
  32. 32.
    Hwang KK, et al. (2012) Enhanced outgrowth of EBV-transformed chronic lymphocytic leukemia B cells mediated by coculture with macrophage feeder cells. Blood. 119:e35–44.CrossRefGoogle Scholar
  33. 33.
    Sotgia F, et al. (2011) Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Breast Cancer Res. 13:213.CrossRefGoogle Scholar
  34. 34.
    Tan J, Buache E, Chenard MP, Dali-Youcef N, Rio MC. (2011) Adipocyte is a non-trivial, dynamic partner of breast cancer cells. Int. J. Dev. Biol. 55:851–9.CrossRefGoogle Scholar
  35. 35.
    Messmer BT, et al. (2005) In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J. Clin. Invest. 115:755–64.CrossRefGoogle Scholar
  36. 36.
    Deaglio S, Malavasi F. (2009) Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation. Haematologica. 94:752–6.CrossRefGoogle Scholar
  37. 37.
    Herman SE, et al. (2013) Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy. Leukemia. 27:2311–21.CrossRefGoogle Scholar
  38. 38.
    Bagnara D, et al. (2011) A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood. 117:5463–72.CrossRefGoogle Scholar
  39. 39.
    Zaugg K, et al. (2011) Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes. Dev. 25:1041–51.CrossRefGoogle Scholar
  40. 40.
    Biswas S, Lunec J, Bartlett K. (2012) Non-glucose metabolism in cancer cells: is it all in the fat? Cancer Metastasis Rev. 31:689–8.CrossRefGoogle Scholar
  41. 41.
    Carracedo A, Cantley LC, Pandolfi PP. (2013) Cancer metabolism: fatty acid oxidation in the limelight. Nat. Rev. Cancer. 13:227–32.CrossRefGoogle Scholar
  42. 42.
    Kaipainen A, et al. (2007) PPARalpha deficiency in inflammatory cells suppresses tumor growth. PLoS One. 2:e260.CrossRefGoogle Scholar
  43. 43.
    Burger JA, et al. (2000) Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 96:2655–63.PubMedGoogle Scholar
  44. 44.
    Pedersen IM, et al. (2002) Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 100:1795–801.CrossRefGoogle Scholar
  45. 45.
    Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckmans P. (1998) Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood. 91:2387–96.PubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s) 2015

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (

Authors and Affiliations

  • Davorka Messmer
    • 1
  • Kymmy Lorrain
    • 1
  • Karin Stebbins
    • 1
  • Yalda Bravo
    • 1
  • Nicholas Stock
    • 1
  • Geraldine Cabrera
    • 1
  • Lucia Correa
    • 1
  • Austin Chen
    • 1
  • Jason Jacintho
    • 1
  • Nicholas Chiorazzi
    • 2
  • Xiao Jie Yan
    • 2
  • David Spaner
    • 3
    • 4
    • 5
  • Peppi Prasit
    • 1
  • Daniel Lorrain
    • 1
  1. 1.Inception SciencesSan DiegoUSA
  2. 2.The Feinstein Institute for Medical ResearchNorth Shore-LIJ Health SystemManhassetUSA
  3. 3.Division of Molecular and Cellular BiologySunnybrook Research InstituteTorontoCanada
  4. 4.Department of Medical BiophysicsUniversity of TorontoTorontoCanada
  5. 5.Department of ImmunologyUniversity of TorontoTorontoCanada

Personalised recommendations